Timing of rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis
Luca Quartuccio, Elena Treppo, Marco Binutti, Giulia Del Frate, Salvatore De Vita
Topics & Concepts
MedicineRituximabCoronavirus disease 2019 (COVID-19)ANCA-Associated Vasculitis2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VasculitisImmunologyAntibodyInternal medicineVirologyInfectious disease (medical specialty)DiseaseOutbreakVasculitis and related conditionsCOVID-19 Clinical Research StudiesHeparin-Induced Thrombocytopenia and Thrombosis